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BACKGROUND
Prophylaxis for gastrointestinal stress ulceration is frequently given to patients in the 
intensive care unit (ICU), but its risks and benefits are unclear.
METHODS
In this European, multicenter, parallel-group, blinded trial, we randomly assigned adults 
who had been admitted to the ICU for an acute condition (i.e., an unplanned admission) 
and who were at risk for gastrointestinal bleeding to receive 40 mg of intravenous panto-
prazole (a proton-pump inhibitor) or placebo daily during the ICU stay. The primary 
outcome was death by 90 days after randomization.
RESULTS
A total of 3298 patients were enrolled; 1645 were randomly assigned to the pantoprazole 
group and 1653 to the placebo group. Data on the primary outcome were available for 
3282 patients (99.5%). At 90 days, 510 patients (31.1%) in the pantoprazole group and 499 
(30.4%) in the placebo group had died (relative risk, 1.02; 95% confidence interval [CI], 
0.91 to 1.13; P = 0.76). During the ICU stay, at least one clinically important event (a com-
posite of clinically important gastrointestinal bleeding, pneumonia, Clostridium difficile 
infection, or myocardial ischemia) had occurred in 21.9% of patients assigned to panto-
prazole and 22.6% of those assigned to placebo (relative risk, 0.96; 95% CI, 0.83 to 1.11). 
In the pantoprazole group, 2.5% of patients had clinically important gastrointestinal 
bleeding, as compared with 4.2% in the placebo group. The number of patients with in-
fections or serious adverse reactions and the percentage of days alive without life support 
within 90 days were similar in the two groups.
CONCLUSIONS
Among adult patients in the ICU who were at risk for gastrointestinal bleeding, mortality 
at 90 days and the number of clinically important events were similar in those assigned 
to pantoprazole and those assigned to placebo. (Funded by Innovation Fund Denmark 
and others; SUP-ICU ClinicalTrials.gov number, NCT02467621.)
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Critically ill patients in the inten-sive care unit (ICU) are at risk for stress-related gastrointestinal bleeding, which is 
associated with adverse outcomes.1 To prevent 
gastrointestinal bleeding in these patients, pro-
phylaxis for stress ulcers is used and is included 
in guidelines for patients who are at risk for 
gastrointestinal bleeding.2 Risk factors for the 
development of gastrointestinal bleeding in the 
ICU include mechanical ventilation, coagulopathy, 
and hepatic or kidney failure.3-5 Proton-pump in-
hibitors are the most commonly used prophylac-
tic acid suppressant in these circumstances,6 and 
they are among the most frequently used off-
label medications in ICUs (they have not been 
approved by the Food and Drug Administration 
as prophylaxis for stress ulcers).7 However, the 
quality of evidence supporting the prophylactic 
use of proton-pump inhibitors in the ICU is lim-
ited.8,9 Concerns have been raised about adverse 
effects associated with this class of drugs, includ-
ing the risk of Clostridium difficile infection, pneu-
monia, and myocardial ischemia, which may 
counterbalance their potential benefits.10-12
We conducted the Stress Ulcer Prophylaxis in 
the Intensive Care Unit (SUP-ICU) trial to evalu-
ate the effects of and adverse events associated 
with the prophylactic use of the proton-pump 
inhibitor pantoprazole in adult patients in the 
ICU who were at risk for gastrointestinal bleed-
ing. We hypothesized that pantoprazole would 
be associated with a lower rate of gastrointesti-
nal bleeding but with higher rates of nosocomial 
infections and myocardial ischemia than placebo 
among these patients.
Me thods
Trial Design and Oversight
We performed screening and randomization be-
tween January 4, 2016, and October 22, 2017, in 
33 ICUs in Denmark, Finland, the Netherlands, 
Norway, Switzerland, and the United Kingdom 
after obtaining institutional approval at each site. 
We obtained written informed consent from the 
patients or their legal surrogates in accordance 
with national regulations. In most institutions, 
if the patient or legal guardian was unable to 
give consent initially, enrollment of patients was 
allowed on an emergency basis (e.g., with con-
sent from a doctor who was independent of the 
trial), followed by consent from relatives and the 
patient to continue participation. If consent was 
withdrawn or not granted, we asked the patient 
or surrogate for permission to continue registra-
tion of trial data and for permission to include 
these data in our analyses. The trial protocol 
and the statistical analysis plan have been pub-
lished elsewhere and are available with the full 
text of this article at NEJM.org.13,14 All the authors 
vouch for the adherence of the trial to the pro-
tocol, the accuracy and completeness of the data 
and analyses, and the reporting of adverse events. 
The members of the steering committee wrote the 
draft of the manuscript and made the final deci-
sion to submit it for publication. The trial was 
funded by Innovation Fund Denmark, which had 
no role in the design of the protocol, the trial 
conduct, or the analyses or reporting of the data. 
There was no commercial support for the trial.
This trial was a multicenter, stratified, parallel-
group, placebo-controlled, blinded clinical trial. 
Randomization was performed with a centralized, 
computer-generated allocation sequence stratified 
according to trial site and the presence or ab-
sence of active hematologic cancer. Patients who 
were admitted to participating ICUs were screened 
and, if eligible, were randomly assigned in a 1:1 
ratio, with the use of permuted blocks of varying 
sizes, to receive pantoprazole or placebo. The 
trial-group assignments were concealed from the 
patients, clinicians, investigators, trial statisticians, 
and members of the data and safety monitoring 
committee. The data and safety monitoring com-
mittee oversaw the conduct of the trial and the 
safety of the participants. Interim analyses were 
planned to be conducted when 1675 and 2500 
patients had been followed for 90 days. The lat-
ter interim analysis was not performed, because 
the target number of patients enrolled was com-
pleted before the 90-day follow-up of 2500 pa-
tients. The trial data were monitored at the sites 
by external monitors in accordance with the 
Good Clinical Practice directive of the European 
Union and centrally by staff from the coordinat-
ing center.
Participants
We screened patients 18 years of age or older 
who were admitted to the ICU for an acute condi-
tion (i.e., excluding elective admissions) and had 
at least one risk factor for clinically important 
gastrointestinal bleeding, including shock, use of 
anticoagulant agents, renal-replacement therapy, 
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mechanical ventilation (expected to last >24 hours), 
any history of liver disease, or any history of or 
ongoing coagulopathy (the full definitions of the 
criteria are provided in the Supplementary Ap-
pendix, available at NEJM.org4,13). We encouraged 
the investigators at all the trial sites to system-
atically complete the screening procedure for all 
patients who fulfilled the inclusion criteria. Pa-
tients were excluded for the reasons shown in 
Figure 1 and in the Supplementary Appendix.
Interventions
Enrolled patients received an intravenous injec-
tion of pantoprazole (40 mg suspended in 10 ml 
of 0.9% sodium chloride) or matching placebo 
(suspended in 10 ml of 0.9% sodium chloride) 
(Fig. S1 in the Supplementary Appendix) as a 
single bolus once daily from randomization until 
ICU discharge or death, for a maximum of 90 
days. If a patient was readmitted to a trial ICU 
within 90 days, the originally assigned trial 
regimen was resumed. All other interventions 
were chosen at the discretion of the clinicians.
Outcomes
The primary outcome was death by 90 days after 
randomization. The secondary outcomes were 
clinically important events in the ICU (defined 
as clinically important gastrointestinal bleeding,4 
new-onset pneumonia,15 C. difficile infection, or 
acute myocardial ischemia; see the Supplemen-
tary Appendix); clinically important gastrointes-
tinal bleeding in the ICU (defined as overt gas-
trointestinal bleeding and at least one of the 
following four features within 24 hours of gas-
trointestinal bleeding, in the absence of other 
causes, in the ICU: a spontaneous decrease in 
systolic blood pressure, mean arterial pressure, 
or diastolic blood pressure of 20 mm Hg or more; 
initiation of treatment with a vasopressor or a 
20% increase in vasopressor dose; a decrease in 
hemoglobin of at least 2 g per deciliter [1.24 mmol 
per liter]; or transfusion of two or more units of 
packed red cells); infectious adverse events in the 
ICU (new-onset pneumonia or C. difficile infec-
tion); serious adverse reactions in the ICU (see 
the Supplementary Appendix); and the percent-
age of days alive without the use of life support 
(mechanical ventilation, circulatory support, or 
renal-replacement therapy; see the Supplementary 
Appendix) within the 90-day period. Data for out-
come measures were obtained from the patients’ 
files by the trial investigators or their delegates. 
For 90-day mortality, regional and national regis-
tries or direct contact with participants or sur-
rogates were used if available.
Statistical Analysis
We estimated that 3350 patients would be re-
quired for the trial to have 90% power to detect 
a between-group difference of 5 percentage points 
in 90-day mortality, corresponding to a 20% dif-
ference in relative risk at a two-sided alpha level 
of 5%, under the assumption of a baseline 90-day 
mortality of 25%.4,13,14 The statistical analysis was 
performed in accordance with the International 
Conference on Harmonisation tripartite guideline 
(Guideline for Good Clinical Practice16) and the 
statistical analysis plan, by an independent statis-
tician who was unaware of the trial-group as-
signments.14 We conducted the primary analysis 
in the intention-to-treat population, defined as all 
patients who underwent randomization except for 
the 59 patients who were excluded after random-
ization; 7 patients did not consent to the use of 
their data, and 52 patients were excluded imme-
diately after randomization before the first dose 
of trial medication because they did not meet the 
inclusion criteria or fulfilled one or more exclu-
sion criteria.17 In the per-protocol population, we 
excluded patients with one or more major proto-
col violations (Table S2 in the Supplementary 
Appendix).16
In the primary analyses, we evaluated data in 
the two groups using a binary logistic regression 
adjusted for trial site and active hematologic can-
cer in the intention-to-treat population18; relative 
risks with 95% confidence intervals were com-
puted as described in the statistical analysis plan 
(see the Supplementary Appendix). We evaluated 
the primary outcome in the per-protocol popula-
tion and in prespecified subgroups defined by 
the presence or absence of any history of liver 
disease, the presence or absence of any history of 
coagulopathy or ongoing coagulopathy, the type 
of ICU admission (medical vs. surgical), the pres-
ence or absence of shock, the use or absence of 
use of mechanical ventilation, and a Simplified 
Acute Physiology Score (SAPS) II19 above 53 or 53 
or lower at baseline. The SAPS II is calculated from 
17 variables and has a total range from 0 to 163, 
with higher scores indicating greater severity of 
disease; a score of 53 was chosen as predicting 
a 50% mortality rate in the original model.
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Figure 1. Screening, Randomization, and Follow-up.
We screened patients who were admitted to the intensive care unit (ICU) for an acute condition (i.e., an unplanned 
admission), were 18 years of age or older, and had at least one risk factor for gastrointestinal bleeding. Patients were 
excluded if there were medical reasons, if they were receiving ongoing daily acid-suppressing therapy in the ICU, or 
if informed consent could not be obtained; 1001 patients met two or more exclusion criteria. A total of 52 patients 
were excluded immediately after randomization and before the first dose of trial agent because they did not meet 
the inclusion criteria or fulfilled one or more exclusion criteria; 7 patients were excluded after randomization because 
the patient or the surrogate did not allow the use of their data. The remaining 267 patients (130 in the pantoprazole 
group and 137 in the placebo group) who withdrew from the trial at their own or their surrogates’ request allowed 
the use of their data, but 20 patients or surrogates in the pantoprazole group and 20 in the placebo group did not 
want further data to be registered except for data on mortality, which we obtained from registries. Some of the pro-
cess variables and some of the secondary outcomes were missing for these 40 patients.
3350 Underwent randomization
10,000 Patients were assessed for eligibility
6650 Were excluded
4197 Had ongoing daily treatment with acid
suppressants
1812 Were excluded because consent could
not be obtained
822 Had gastrointestinal bleeding during
index hospital admission
492 Were withdrawn from active therapy
or were brain dead
210 Underwent organ transplantation during 
index hospital admission
207 Had peptic ulcer confirmed by endoscopy
or other method during index hospital
admission
35 Had a contraindication to pantoprazole
17 Were pregnant
4 Underwent duplicate randomization
during a second ICU admission
52 Were excluded before receiving the
first dose of pantoprazole or placebo
because they underwent randomization
in error
1645 Were assigned to pantoprazole
274 Discontinued trial regimen
130 Did not give consent or withdrew
consent
100 Had indication for open-label acid
suppression
44 Had other clinical decision
1653 Were assigned to placebo
319 Discontinued trial regimen
137 Did not give consent or withdrew
consent
148 Had indication for open-label acid
suppression
34 Had other clinical decision
3 Were excluded at 90-day
follow-up
1 Withdrew consent for the
use of data
2 Were lost to 90-day 
follow-up
13 Were excluded at 90-day
follow-up
6 Withdrew consent for the
use of data
7 Were lost to 90-day
follow-up
1642 (99.8%) Were included in the analyses
of mortality
1644 (99.9%) Were included in the secondary
outcome analyses
1640 (99.2%) Were included in the analyses
of mortality
1647 (99.6%) Were included in the secondary
outcome analyses
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For secondary analyses, we evaluated all di-
chotomous outcomes in binary logistic regression 
analyses of the intention-to-treat population ad-
justed for stratification variables and predefined 
risk factors at baseline (age, type of admission 
[medical, elective surgery, or emergency surgery], 
and the Sepsis-related Organ Failure Assessment 
[SOFA] score assessed in the 24 hours before 
randomization).20 The SOFA score is made up of 
subscores ranging from 0 to 4 for each of six 
organ systems (cerebral, circulatory, pulmonary, 
hepatic, renal, and coagulative), resulting in an 
aggregated score that ranges from 0 to 24, with 
higher scores indicating more severe organ failure. 
We also performed unadjusted chi-square testing 
for the binary outcome measures. We analyzed 
percentages of days alive without life support in 
the 90-day period with the van Elteren test (with 
adjustment for site only), because the assump-
tions for Poisson or negative binomial distribu-
tions were not met.21 There was no adjustment for 
multiple comparisons of secondary outcomes, 
and the results are reported as point estimates 
with unadjusted 95% confidence intervals. There 
was no imputation for missing data (details are 
provided in the Supplementary Appendix). A total 
of 9 patients were lost to 90-day follow-up. We 
performed analyses using SAS software, version 
9.4 (SAS Institute), and R software, version 3.4.3 
(R Foundation), and considered a two-sided P value 
of less than 0.05 to indicate statistical signifi-
cance for the primary outcome with 95% con-
fidence intervals.
R esult s
Trial Population
From January 2016 through October 2017, a total 
of 3298 patients were enrolled in the trial; 1645 
were randomly assigned to receive pantoprazole, 
and 1653 were assigned to receive placebo. We 
obtained data on 90-day vital status for 3282 
patients (99.5%; 1642 in the pantoprazole group 
and 1640 in the placebo group) (Fig. 1). The 
characteristics of the patients at baseline were 
similar in the two groups, with the exception of 
chronic lung disease, coagulopathy, and emer-
gency surgery (Table 1).
During the 90-day trial period, patients in each 
group stayed in the ICU for a median of 6 days 
after randomization (interquartile range, 4 to 11 
in each group), and patients in each group re-
ceived the trial agent for a median of 4 days 
(interquartile range, 2 to 9 in each group); 274 
of 1644 patients (16.7%) in the pantoprazole group 
and 319 of 1647 (19.4%) in the placebo group 
discontinued the trial regimen in the ICU for 
reasons shown in Figure 1. The number of pa-
tients with major protocol violations was 46 
(2.8%) in the pantoprazole group and 43 (2.6%) 
in the placebo group (Table S2 in the Supple-
mentary Appendix). On the first trial day, 58.2% 
of patients in the pantoprazole group and 56.4% 
in the placebo group received enteral feeding 
(Table S3 in the Supplementary Appendix); pa-
tients in each group received enteral feeding for 
a median of 4 days (interquartile range, 2 to 10 in 
each group) in the ICU.
Outcomes
At 90 days after randomization, 510 of 1642 pa-
tients (31.1%) in the pantoprazole group and 499 
of 1640 (30.4%) in the placebo group had died 
(relative risk, 1.02; 95% confidence interval [CI], 
0.91 to 1.13; P = 0.76) (Table 2 and Fig. 2). The 
results were similar in the analysis with adjust-
ment for baseline risk factors and in the per-
protocol population (Tables S4, S5, and S6 in the 
Supplementary Appendix). In predefined subgroup 
analyses, there was no heterogeneity in the ef-
fect of pantoprazole as compared with placebo on 
mortality at 90 days between patients with and 
patients without a history of liver disease, a his-
tory of or ongoing coagulopathy, shock, or me-
chanical ventilation, or between patients with 
different types of ICU admission (Fig. 2). We 
found heterogeneity in the estimate of the inter-
vention effect among patients with higher as 
compared with lower baseline severity of disease 
(defined as a SAPS II of >53 and ≤53, respec-
tively) (Fig. 2).
A total of 360 (21.9%) of 1644 patients in the 
pantoprazole group and 372 (22.6%) of 1647 in 
the placebo group had one or more clinically 
important events in the ICU (relative risk, 0.96; 
95% CI, 0.83 to 1.11 [not adjusted for multiple 
comparisons]) (Table 2). In the pantoprazole 
group, 41 patients (2.5%) had clinically impor-
tant gastrointestinal bleeding, as compared with 
69 (4.2%) in the placebo group. The proportions 
of patients in each group with the other second-
ary outcomes and with single components of the 
composite outcome were similar in the two 
groups and are shown in Table 2 without P values 
because of the lack of adjustment for multiple 
comparisons (also see Table S7 in the Supple-
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Characteristic
Pantoprazole 
(N = 1644)
Placebo 
(N = 1647)
Median age (IQR) — yr 67 (56–75) 67 (55–75)
Male sex — no. (%) 1039 (63) 1067 (65)
Coexisting conditions — no. (%)
Chronic lung disease† 351 (21) 306 (19)
Previous myocardial infarction 156 (9) 142 (9)
Chronic heart failure‡ 100 (6) 99 (6)
Use of glucocorticoids§ 35 (2) 27 (2)
Hematologic cancer¶ 64 (4) 55 (3)
Metastatic cancer ‖ 56 (3) 55 (3)
AIDS** 6 (<1) 1 (<1)
Coagulopathy†† 352 (21) 299 (18)
Admission to university hospital — no. (%) 1183 (72) 1189 (72)
Median time from ICU admission to randomization (IQR) — hr 15 (5–28) 14 (6–25)
Median time from hospital admission to randomization (IQR) — days 1 (1–3) 1 (1–3)
ICU admission type — no. (%)
Medical 998 (61) 941 (57)
Emergency surgery 490 (30) 558 (34)
Elective surgery 156 (9) 148 (9)
Use of invasive mechanical ventilation — no. (%) 1273 (77) 1316 (80)
Use of vasopressors or inotropes — no. (%) 1103 (67) 1093 (66)
Use of any renal-replacement therapy — no. (%) 123 (7) 99 (6)
Median SAPS II (IQR)‡‡ 49 (39–59) 48 (37–59)
Median SOFA score (IQR)§§ 9 (7–11) 9 (7–11)
*  There were no significant differences between the groups with regard to any baseline characteristic except chronic lung disease (P = 0.05), 
emergency surgery (P = 0.01), and coagulopathy (P = 0.02). A full list of risk factors for gastrointestinal bleeding is provided in Table S1 in 
the Supplementary Appendix.
†  Chronic lung disease was defined as any history of chronic obstructive pulmonary disease, asthma, or other chronic lung disease or treat-
ment with any relevant drug indicating this at the time of admission to hospital.
‡  Chronic heart failure was defined as New York Heart Association (NYHA) functional class III or IV. Patients with NYHA class III heart fail-
ure have marked limitations in physical activity due to symptoms (fatigue, palpitation, or dyspnea) even during less-than-ordinary activity 
(e.g., walking short distances of 20 to 100 m or walking up one flight of stairs); patients are comfortable only at rest. Patients with NYHA 
class IV heart failure are not able to perform any physical activity without discomfort (fatigue, palpitation, or dyspnea); symptoms are 
present even at rest, and patients are mostly bedbound.
§  Use of glucocorticoids was defined as treatment with at least 0.3 mg per kilogram of body weight per day of prednisolone or equivalent for 
at least 1 month in the 6 months before ICU admission.
¶  Hematologic cancer included acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lympho-
cytic leukemia, Hodgkin’s disease, non-Hodgkin’s lymphoma (e.g., small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular 
lymphoma, mantle-cell lymphoma, hairy-cell leukemia, marginal-zone lymphoma, Burkitt’s lymphoma, post-transplantation lymphoprolif-
erative disorder, T-cell prolymphocytic leukemia, B-cell prolymphocytic leukemia, Waldenström’s macroglobulinemia, and other natural-
killer-cell or T-cell lymphomas), and multiple myeloma or plasma cell myeloma.
‖  Metastatic cancer was defined as metastasis proved by means of surgery, computed tomography, or any other method.
**  Acquired immunodeficiency syndrome (AIDS) was defined as one or more AIDS-defining diseases (e.g., Pneumocystis jiroveci pneumonia, 
Kaposi’s sarcoma, lymphoma, tuberculosis, and toxoplasma infection) in a patient with human immunodeficiency virus infection.
††  Coagulopathy included both acute coagulopathy (defined as a platelet count of <50×109 per liter, an international normalized ratio >1.5,  
or a prothrombin time of >20 seconds at ICU admission) and a history of coagulopathy (defined as coagulopathy within 6 months before 
hospital admission).
‡‡  The Simplified Acute Physiology Score (SAPS) II19 was assessed in the 24 hours before randomization. The score is calculated from 17 vari-
ables and ranges from 0 to 163, with higher scores indicating a higher severity of disease (Table S9 in the Supplementary Appendix). Data 
were missing for 134 patients in the pantoprazole group and 115 patients in the placebo group, and their values are not included here.
§§  The Sepsis-related Organ Failure Assessment (SOFA)20 score was assessed in the 24 hours before randomization. The score is a measure 
of organ failure, with subscoring ranging from 0 to 4 for each of six organ systems (cerebral, circulatory, pulmonary, hepatic, renal, and 
coagulative). The aggregated score ranges from 0 to 24, with higher scores indicating more severe organ failure (Table S10 in the Supple-
mentary Appendix). Data were missing for 108 patients in the pantoprazole group and 85 patients in the placebo group, and their values 
are not included here. There was no imputation for missing data.
Table 1. Characteristics of the Patients at Baseline.*
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mentary Appendix). Details of the episodes of 
gastrointestinal bleeding are provided in Table S8 
in the Supplementary Appendix.
Discussion
In this international, blinded, placebo-controlled, 
randomized trial involving adult patients in the 
ICU who were at risk for gastrointestinal bleed-
ing, we found that 90-day mortality, percentages 
of days alive without the use of life support, and 
numbers of patients with clinically important 
events, infectious adverse events, or serious ad-
verse reactions were similar between those treated 
with pantoprazole and those who received pla-
cebo. Fewer patients in the pantoprazole group 
than in the placebo group had clinically impor-
tant gastrointestinal bleeding in the ICU, and the 
95% confidence intervals (which were not ad-
justed for multiple comparisons) for the relative 
risk did not cross 1; however, the absence of 
correction for multiple comparisons of secondary 
outcomes limits inferences from this observation. 
The results of this trial apply only to patients who 
meet the entry criteria used in the trial, including 
a high risk of gastrointestinal bleeding.
Our results are similar to those obtained in a 
recent network meta-analysis, in which no sig-
nificant differences were found in the rates of 
death or infectious complications between pa-
tients receiving placebo or no prophylaxis and 
those receiving proton-pump inhibitors; the latter 
group, however, did have lower rates of clini-
cally important gastrointestinal bleeding.22 The 
results of the current trial did not reproduce those 
of observational studies, which have suggested 
an increased risk of infectious complications 
and myocardial ischemia in association with the 
use of proton-pump inhibitors.10-12 We found no 
significant differences between the pantoprazole 
group and the placebo group in the rates of 
these events in the full trial population, but we 
did find an interaction between the intervention 
effect and disease severity that suggested higher 
90-day mortality among patients who had more 
severe disease and received pantoprazole. This 
may be a chance finding, but it warrants further 
study.
The strengths of our trial include the large 
sample size and variety of ICUs and countries 
involved, ref lecting different practice patterns. 
The trial protocol was pragmatic, so that routine 
Outcomes Pantoprazole Placebo
Relative Risk 
 (95% CI)* P Value†
Primary outcome: death by day 90 — no./total no. (%) 510/1642 (31.1) 499/1640 (30.4) 1.02 (0.91–1.13) 0.76
Secondary outcomes
One or more clinically important events — no./total no. (%)‡ 360/1644 (21.9) 372/1647 (22.6) 0.96 (0.83–1.11) —
One or more episodes of clinically important gastrointestinal 
bleeding — no./total no. (%)
41/1644 (2.5) 69/1647 (4.2) 0.58 (0.40–0.86) —
One or more infectious adverse events — no./total no. (%)§ 276/1644 (16.8) 279/1647 (16.9) 0.99 (0.84–1.16) —
Severe adverse reaction — no./total no. (%)¶ 0/1644 (0) 0/1647 (0) — —
Median percentage of days alive without the use of life  
support (IQR)‖
92 (60–97) 92 (65–97) — —
*  Confidence intervals were not adjusted for the comparisons of multiple secondary outcomes.
†  Logistic-regression analyses were adjusted for the stratification variables (site and hematologic cancer). The results of the unadjusted out-
come analyses and the fully adjusted analyses are presented in Tables S4 and S6 in the Supplementary Appendix. Secondary outcomes are 
presented without P values because of the lack of adjustment for multiple comparisons.
‡  Clinically important events included clinically important gastrointestinal bleeding, pneumonia, Clostridium difficile infection, and myocardial 
ischemia.
§  Infectious adverse events included pneumonia and C. difficile infection.
¶  Severe adverse reactions were defined as anaphylactic reactions, agranulocytosis, pancytopenia, acute hepatic failure, the Stevens–Johnson 
syndrome, toxic epidermal necrolysis, interstitial nephritis, and angioedema related to the intervention (as judged by the treating clinicians 
and investigators).14 Specific events that were adjudicated as not to being related to pantoprazole or placebo, including the reasoning behind 
each adjudication, are described in Table S11 in the Supplementary Appendix.
‖  The percentage of days alive without the use of life support was calculated as the number of days without the use of invasive or noninvasive 
mechanical ventilation, infusion of vasopressor or inotropic agents, or any form of renal-replacement therapy, divided by the number of days 
alive within the 90-day follow-up period.
Table 2. Primary and Secondary Outcome Measures.
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practice was maintained except for the prophy-
lactic use of gastric acid suppressors.
The limitations of the trial include the lack of 
assessment of other medical interventions and 
the limited power of the trial to detect differ-
ences in some outcome measures and in the 
subgroup analyses; in addition, the absence of 
reported serious adverse reactions to pantopra-
zole suggests underreporting, as may have oc-
curred in another large trial of glucocorticoids 
in the ICU setting.23 We did not mandate diagnos-
tic endoscopy to assess the source of bleeding 
and were therefore unable to differentiate be-
tween stress ulcers and other causes of gastroin-
testinal bleeding. Some baseline variables differed 
between the groups, but the predefined second-
ary analysis adjusting for some of these differ-
ences supported the primary result. We did not 
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determine whether patients had used acid sup-
pressants before ICU admission or were receiving 
enteral nutrition at baseline. The composite sec-
ondary outcome we used is not one that is nor-
mally reported. Finally, the trial was powered for 
an absolute between-group difference in 90-day 
mortality of 5 percentage points, a margin that 
may be considered large.24
In conclusion, in this trial involving adult 
patients who were admitted to the ICU for an 
acute condition and were at risk for gastrointes-
tinal bleeding, we found no significant differ-
ences between pantoprazole and placebo with 
regard to either 90-day mortality or the number 
of patients with a composite outcome of four 
clinically important events.
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Panel A shows the survival curves with data censored 
at day 90 for the two groups in the intention-to-treat 
population. The nine patients who were lost to 90-day 
follow-up — two patients in the pantoprazole group 
and seven patients in the placebo group — were included 
in the survival curves until the last day they were known 
to be alive; at that time point, data from these patients 
were censored. One patient in the pantoprazole group 
was known to be dead at day 90, but the date of death 
was unknown. This patient was excluded from the sur-
vival curves. Panel B shows relative risks with 95% con-
fidence intervals for the primary outcome measure of 
death at day 90 in the pantoprazole group as compared 
with the placebo group, among all the patients and  
in the six predefined subgroups, assessed by logistic-
regression analysis with adjustment for the stratification 
variables. Shock was defined as at least one of the fol-
lowing: systolic blood pressure of less than 90 mm Hg, 
mean arterial pressure of less than 70 mm Hg, use of 
vasopressors or inotropes (norepinephrine, epinephrine, 
phenylephrine, vasopressin or dopamine, dobutamine, 
milrinone, or levosimendan), or a lactate level of more 
than 4 mmol per liter. Coagulopathy included both acute 
coagulopathy, defined as a platelet count of less than 
50×109 per liter, an international normalized ratio of 
more than 1.5, or a prothrombin time of more than  
20 seconds at ICU admission, and a history of coagu-
lopathy, defined as coagulopathy within 6 months be-
fore hospital admission. A history of liver disease was 
defined as portal hypertension; cirrhosis proved by biop-
sy, computed tomography, or ultrasonography; history 
of variceal bleeding; or hepatic encephalopathy in the 
medical history. A medical admission was defined as a 
hospital admission during which no surgery was per-
formed or an ICU admission in which surgery had been 
performed more than 1 week before admission. The Sim-
plified Acute Physiology Score (SAPS) II was calculated 
from 17 baseline variables and ranges from 0 to 163, with 
higher scores indicating greater severity of disease. One 
or more variables were missing for 134 patients in the 
pantoprazole group and 115 patients in the placebo 
group for the calculation of the SAPS II; these patients 
were not included in the SAPS II subgroup analysis.
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